Literature DB >> 23411126

An open clinical trial assessing a novel training program for social cognitive impairment in schizophrenia.

Pamela Marsh1, Robyn Langdon, Jonathan McGuire, Anthony Harris, Vince Polito, Max Coltheart.   

Abstract

OBJECTIVE: Social cognition is profoundly impaired in patients with schizophrenia. This study describes 'Mental-State Reasoning Training for Social Cognitive Impairment' (SoCog-MSRT), a 5-week program developed to improve social cognition in patients with schizophrenia. We aimed to investigate the feasibility of implementing SoCog-MSRT in a rehabilitation setting and to evaluate whether our training methods produced improvements. METHOD The feasibility and benefits of SoCog-MSRT were evaluated in an open clinical trial with 14 participants with schizophrenia or schizoaffective disorder. Training comprised 10 twice-weekly sessions, for 5 weeks, with a pre- and post-training assessment.
RESULTS: There were significant improvements on: (a) a classic false-belief test of Theory of Mind (ToM); (b) inferring complex mental states from the eyes; and (c) a self-reported measure of social understanding. Some of these improvements were associated with baseline levels of working memory and premorbid Intelligence Quotient (IQ). CONCLUSIONS SoCog-MSRT can improve ToM abilities and social understanding, but individuals with poorer working memory and lower premorbid IQ may be less able to benefit from this type of training.

Entities:  

Mesh:

Year:  2013        PMID: 23411126     DOI: 10.1177/1039856213475683

Source DB:  PubMed          Journal:  Australas Psychiatry        ISSN: 1039-8562            Impact factor:   1.369


  7 in total

1.  Online Social Cognition Training in Schizophrenia: A Double-Blind, Randomized, Controlled Multi-Site Clinical Trial.

Authors:  Mor Nahum; Hyunkyu Lee; Melissa Fisher; Michael F Green; Christine I Hooker; Joseph Ventura; Joshua T Jordan; Annika Rose; Sarah-Jane Kim; Kristen M Haut; Michael M Merzenich; Sophia Vinogradov
Journal:  Schizophr Bull       Date:  2021-01-23       Impact factor: 9.306

2.  A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis.

Authors:  Cristina Cacciotti-Saija; Robyn Langdon; Philip B Ward; Ian B Hickie; Elizabeth M Scott; Sharon L Naismith; Loretta Moore; Gail A Alvares; Marie Antoinette Redoblado Hodge; Adam J Guastella
Journal:  Schizophr Bull       Date:  2014-06-23       Impact factor: 9.306

3.  Randomized controlled trial of computer-based treatment of social cognition in schizophrenia: the TRuSST trial protocol.

Authors:  Annika Rose; Sophia Vinogradov; Melissa Fisher; Michael F Green; Joseph Ventura; Christine Hooker; Michael Merzenich; Mor Nahum
Journal:  BMC Psychiatry       Date:  2015-07-03       Impact factor: 3.630

Review 4.  A systematic review on improving cognition in schizophrenia: which is the more commonly used type of training, practice or strategy learning?

Authors:  Karine Paquin; Alexa Larouche Wilson; Caroline Cellard; Tania Lecomte; Stéphane Potvin
Journal:  BMC Psychiatry       Date:  2014-05-14       Impact factor: 3.630

5.  A quasi-randomized feasibility pilot study of specific treatments to improve emotion recognition and mental-state reasoning impairments in schizophrenia.

Authors:  Pamela Jane Marsh; Vince Polito; Subba Singh; Max Coltheart; Robyn Langdon; Anthony W Harris
Journal:  BMC Psychiatry       Date:  2016-10-24       Impact factor: 3.630

6.  Randomized Clinical Trial with e-MotionalTraining® 1.0 for Social Cognition Rehabilitation in Schizophrenia.

Authors:  Yolanda Maroño Souto; Miriam Vázquez Campo; Francisco Díaz Llenderrozas; Marina Rodríguez Álvarez; Raimundo Mateos; Alejandro García Caballero
Journal:  Front Psychiatry       Date:  2018-02-26       Impact factor: 4.157

Review 7.  The Importance of Social Cognition in Improving Functional Outcomes in Schizophrenia.

Authors:  Afzal Javed; Asha Charles
Journal:  Front Psychiatry       Date:  2018-04-24       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.